Hubei Biocause Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was CNY 22,922.959 million compared to CNY 26,980.244 million a year ago. Net income was CNY 314.813 million compared to CNY 520.414 million a year ago. Basic earnings per share from continuing operations was CNY 0.064 compared to CNY 0.11 a year ago.